跳至主要内容
临床试验/NCT03225963
NCT03225963Unknown不适用

Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

Taichung Veterans General Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2015年8月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
Response of bevacizumab therapy.

研究概览

简要总结

Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

详细描述

Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age older than 20 year old.
  • Glioblastoma patients who will receive chemoradiation treatment.

排除标准

  • 未提供

结局指标

主要结局

Response of bevacizumab therapy.

时间窗: 3 months after bevacizumab therapy

Base on the image after bevacizumab therapy (after recurrence)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验